Market Closed -
BME
11:35:10 2024-05-03 am EDT
|
5-day change
|
1st Jan Change
|
8.685
EUR
|
+0.35%
|
|
+1.34%
|
+3.09%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,555
|
1,945
|
2,031
|
1,641
|
1,764
|
1,819
|
-
|
-
|
Enterprise Value (EV)
1 |
2,939
|
2,338
|
2,197
|
1,756
|
1,732
|
1,738
|
1,704
|
1,576
|
P/E ratio
|
24.4
x
|
24.8
x
|
-49.1
x
|
452
x
|
-42.1
x
|
84.4
x
|
30.3
x
|
17.8
x
|
Yield
|
1.37%
|
1.74%
|
1.68%
|
-
|
2.26%
|
2.15%
|
2.18%
|
2.25%
|
Capitalization / Revenue
|
3
x
|
2.41
x
|
2.51
x
|
1.9
x
|
1.97
x
|
1.87
x
|
1.7
x
|
1.53
x
|
EV / Revenue
|
3.44
x
|
2.9
x
|
2.71
x
|
2.03
x
|
1.94
x
|
1.79
x
|
1.59
x
|
1.32
x
|
EV / EBITDA
|
9.66
x
|
9.81
x
|
9.33
x
|
8.85
x
|
9.95
x
|
9.36
x
|
7.46
x
|
5.68
x
|
EV / FCF
|
20.8
x
|
16.8
x
|
13.5
x
|
45.5
x
|
-26.3
x
|
24.1
x
|
18.9
x
|
10.4
x
|
FCF Yield
|
4.8%
|
5.96%
|
7.41%
|
2.2%
|
-3.8%
|
4.15%
|
5.28%
|
9.61%
|
Price to Book
|
2.02
x
|
1.49
x
|
1.57
x
|
-
|
1.13
x
|
1.19
x
|
1.17
x
|
1.13
x
|
Nbr of stocks (in thousands)
|
174,555
|
178,116
|
179,777
|
181,515
|
209,394
|
209,394
|
-
|
-
|
Reference price
2 |
14.64
|
10.92
|
11.30
|
9.040
|
8.425
|
8.685
|
8.685
|
8.685
|
Announcement Date
|
2/24/20
|
2/22/21
|
2/21/22
|
2/20/23
|
2/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
853.1
|
807.4
|
809.8
|
863.2
|
894.5
|
971.5
|
1,071
|
1,190
|
EBITDA
1 |
304.2
|
238.3
|
235.6
|
198.3
|
174.1
|
185.6
|
228.4
|
277.3
|
EBIT
1 |
174.8
|
115.2
|
115.7
|
46.87
|
49.8
|
54.17
|
97.46
|
132.8
|
Operating Margin
|
20.49%
|
14.27%
|
14.28%
|
5.43%
|
5.57%
|
5.58%
|
9.1%
|
11.16%
|
Earnings before Tax (EBT)
1 |
128.3
|
79.24
|
-9.085
|
31.03
|
-17.19
|
37.86
|
74.58
|
122.2
|
Net income
1 |
105.9
|
74.28
|
-40.86
|
4.281
|
-38.47
|
25.16
|
62.12
|
101.7
|
Net margin
|
12.41%
|
9.2%
|
-5.05%
|
0.5%
|
-4.3%
|
2.59%
|
5.8%
|
8.54%
|
EPS
2 |
0.6000
|
0.4400
|
-0.2300
|
0.0200
|
-0.2000
|
0.1029
|
0.2869
|
0.4874
|
Free Cash Flow
1 |
141.1
|
139.4
|
162.7
|
38.6
|
-65.82
|
72.1
|
89.95
|
151.5
|
FCF margin
|
16.53%
|
17.26%
|
20.09%
|
4.47%
|
-7.36%
|
7.42%
|
8.4%
|
12.73%
|
FCF Conversion (EBITDA)
|
46.37%
|
58.5%
|
69.06%
|
19.47%
|
-
|
38.85%
|
39.39%
|
54.63%
|
FCF Conversion (Net income)
|
133.19%
|
187.67%
|
-
|
901.66%
|
-
|
286.56%
|
144.79%
|
149.01%
|
Dividend per Share
2 |
0.2000
|
0.1900
|
0.1900
|
-
|
0.1900
|
0.1866
|
0.1890
|
0.1957
|
Announcement Date
|
2/24/20
|
2/22/21
|
2/21/22
|
2/20/23
|
2/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
426
|
425.9
|
175.8
|
208.1
|
218.8
|
217.8
|
436.6
|
197.2
|
229.4
|
232
|
234.1
|
466.1
|
208.5
|
219.9
|
235.9
|
249.6
|
235.6
|
243.7
|
EBITDA
1 |
137.2
|
136.6
|
44.6
|
54.4
|
50.3
|
48
|
107.6
|
38.8
|
51.9
|
51.8
|
49.5
|
101.3
|
36.9
|
35.9
|
44.6
|
50.8
|
42.1
|
45.1
|
EBIT
1 |
75.3
|
77.6
|
15.1
|
22.96
|
30.3
|
17.9
|
48.2
|
7.9
|
-9.234
|
20.3
|
18.58
|
38.88
|
5.9
|
5.4
|
15
|
-
|
-
|
-
|
Operating Margin
|
17.68%
|
18.22%
|
8.59%
|
11.03%
|
13.85%
|
8.22%
|
11.04%
|
4.01%
|
-4.02%
|
8.75%
|
7.94%
|
8.34%
|
2.83%
|
2.46%
|
6.36%
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
50.42
|
-26.91
|
7.8
|
10.02
|
28.1
|
13.7
|
41.8
|
-18.5
|
7.727
|
7.7
|
12.72
|
28.12
|
8.4
|
-53.69
|
7
|
14.6
|
5.9
|
8.9
|
Net income
1 |
42.37
|
-42.85
|
3.447
|
-1.459
|
20.4
|
6.9
|
27.3
|
-16.4
|
-6.619
|
7.7
|
4.315
|
12.02
|
1.59
|
-52.07
|
2.8
|
5.9
|
2.4
|
3.6
|
Net margin
|
9.95%
|
-10.06%
|
1.96%
|
-0.7%
|
9.32%
|
3.17%
|
6.25%
|
-8.32%
|
-2.88%
|
3.32%
|
1.84%
|
2.58%
|
0.76%
|
-23.68%
|
1.19%
|
2.36%
|
1.02%
|
1.48%
|
EPS
2 |
0.2500
|
-0.2400
|
0.0200
|
-0.0100
|
0.1100
|
0.0400
|
-
|
-0.0900
|
-0.0400
|
-
|
-
|
-
|
-
|
-
|
0.0100
|
0.0300
|
0.0100
|
0.0200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/27/20
|
7/26/21
|
11/15/21
|
2/21/22
|
5/9/22
|
7/25/22
|
7/25/22
|
11/10/22
|
2/20/23
|
5/8/23
|
7/24/23
|
7/24/23
|
11/9/23
|
2/19/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
383
|
393
|
166
|
115
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
32.3
|
81
|
115
|
242
|
Leverage (Debt/EBITDA)
|
1.259
x
|
1.647
x
|
0.7025
x
|
0.5788
x
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
141
|
139
|
163
|
38.6
|
-65.8
|
72.1
|
90
|
151
|
ROE (net income / shareholders' equity)
|
11%
|
5.75%
|
6.29%
|
2.57%
|
1.12%
|
1.87%
|
4.36%
|
6.64%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
1.56%
|
0.69%
|
0.83%
|
2%
|
3.39%
|
Assets
1 |
-
|
-
|
-
|
274.1
|
-5,577
|
3,030
|
3,102
|
2,998
|
Book Value Per Share
2 |
7.250
|
7.320
|
7.190
|
-
|
7.430
|
7.310
|
7.450
|
7.660
|
Cash Flow per Share
2 |
1.560
|
0.9800
|
1.320
|
0.7200
|
0.4700
|
0.5600
|
0.6500
|
0.7600
|
Capex
1 |
135
|
25.7
|
71.2
|
117
|
159
|
82.6
|
74.5
|
80.4
|
Capex / Sales
|
15.83%
|
3.18%
|
8.79%
|
13.5%
|
17.81%
|
8.5%
|
6.96%
|
6.75%
|
Announcement Date
|
2/24/20
|
2/22/21
|
2/21/22
|
2/20/23
|
2/19/24
|
-
|
-
|
-
|
Last Close Price
8.685
EUR Average target price
11.21
EUR Spread / Average Target +29.06% Consensus |
1st Jan change
|
Capi.
|
---|
| +3.09% | 1.96B | | +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | +8.08% | 167B | | -3.40% | 157B |
Other Pharmaceuticals
|